GKV Capital Management’s Moderna MRNA Stock Holding History

GKV Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17	Closed	-$482	–	143
2025 Q1	$482	Hold	17	–	–	﹤0.01%	165
2024 Q4	$707	Buy	+17	New	+$813	﹤0.01%	160

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GKV Capital Management's MRNA Position: Q2 2025 in Review

GKV Capital Management sold out of Moderna (MRNA) in Q2 2025, closing a stake of 17 shares — an estimated $482 sold.

GKV Capital Management first reported a position in MRNA in Q4 2024 and held it in 2 quarters. The position peaked at $707 in Q4 2024. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

GKV Capital Management reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
GKV Capital Management sold 17 Moderna shares in Q2 2025, an estimated $482.
GKV Capital Management first reported a position in Moderna in Q4 2024 and held it in 2 quarters.
GKV Capital Management's Moderna position peaked at $707 in Q4 2024.
674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on GKV Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.